INCIDENCE OF BENIGN PATHOLOGIC LESIONS AT PARTIAL NEPHRECTOMY FOR RENAL MASSES PRESUMED TO BE RENAL CELL CARCINOMA: JAPANESE DUAL-CENTER EXPERIENCE WITH 176 CONSECUTIVE PATIENTS

2008 ◽  
Vol 179 (4S) ◽  
pp. 332-332
Author(s):  
Yasuhisa Fujii ◽  
Yoshinobu Komai ◽  
Junji Yonese ◽  
Satoru Kawakami ◽  
Kazutaka Saito ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Renal Cell ◽  
Renal Masses ◽  
Pathologic Lesions

scholarly journals Bilateral renal cell carcinoma operated as right radical nephrectomy and left partial nephrectomy with histopathologically confirmed R0 resection

2020 ◽  
Vol 7 (6) ◽  
pp. 2043
Author(s):  
Syed Aadil Shadaab Andrabi ◽  
Syed Mushtaq Ahmad Shah
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Renal Cell ◽  
Radical Nephrectomy ◽  
Histopathological Examination ◽  
Renal Tumors ◽  
R0 Resection ◽  
Renal Cell Carcinomas ◽  
Renal Masses

Bilateral renal tumors remain relatively uncommon, accounting for 1-5% of patients with renal cell carcinoma. Most sporadic renal cell carcinomas are unilateral and unifocal. Bilateral involvement can be synchronous or asynchronous and is found in 2-4% of sporadic renal cell carcinomas. We report a case of 70 years old male who was incidentally found to have bilateral renal masses. Right sided radical nephrectomy and left partial nephrectomy was performed. Histopathological examination of the specimen revealed clear cell carcinoma and confirmed R0 resection. The patient was discharged on 7th postoperative day.

scholarly journals 1398 Active Surveillance Vs. Partial Nephrectomy in Small Renal Masses: Overall and Cancer Specific Survival in A Retrospective Single Centre Study

2021 ◽  
Vol 108 (Supplement_6) ◽  
Author(s):  
S Shafi ◽  
O Kouli ◽  
G Nabi
Keyword(s):  
Renal Cell Carcinoma ◽  
Multivariate Analysis ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Active Surveillance ◽  
Renal Cell ◽  
Tumour Size ◽  
Cancer Specific Survival ◽  
Renal Masses ◽  
Elderly Individuals

Abstract Introduction Currently, the gold standard for T1a renal cell carcinoma treatment is partial nephrectomy (PN). However, active surveillance (AS) is increasing in elderly individuals with co-morbidities. Our hypothesis was that individuals choosing active surveillance would have similar cancer specific survival as partial nephrectomy. Method This retrospective study used electronic notes to collect patient data presenting with T1a renal cell carcinoma, identified over a 15-year period. Primary outcomes were to compare the survival outcomes of these patients while being related to their comorbidities using the Charlson Comorbidity Index (CCI). Results 183 patients were identified with 62 (35%) and 121 (65%) undergoing PN and AS respectively. Patients treated with AS were older (mean age of 66 years vs 58 years; P < 0.001) and had a higher CCI (median CCI 3 vs 2; P = 0.001). Overall, a total of 4 (6.5%) and 55 (45.5%) patients died from any cause after PN and AS respectively, with deaths attributed to kidney cancer was 2 (3.2%), and 10 (8.2%) respectively. Multivariate analysis showed only age >70 affected overall survival independently between the two groups (HR 5.85; CI 3.29-10.42; P < 0.001). Tumour size showed to be the only independent variable on cancer specific survival (HR 2.51; CI 1.14 -5.53; P = 0.023). No difference was seen between the treatment options in multivariate analysis in both overall and cancer specific survival. Conclusions The study agreed with the hypothesis of similar cancer specific survival. Highlighting for elderly individuals with significant co-morbidities, there is no observed benefit for undergoing partial resection.

Partial nephrectomy in the setting of metastatic renal cell carcinoma.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 440-440
Author(s):  
Kara Babaian ◽  
Surena F. Matin ◽  
Pheroze Tamboli ◽  
Nizar M. Tannir ◽  
Eric Jonasch ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Metastatic Disease ◽  
Renal Cell ◽  
Renal Mass ◽  
Cytoreductive Nephrectomy ◽  
Cancer Specific Survival ◽  
Renal Masses

440 Background: Up to one-third of patients with renal cell carcinoma present with metastatic disease (mRCC). Cytoreductive nephrectomy remains the standard of care for appropriately selected patients. However, cytoreductive nephrectomy is not always practical. We sought to identify the indications and outcomes for partial nephrectomy (PN) in our cohort of patients with mRCC, with particular attention to different PN subgroups. Methods: Using our institutional database, 30 patients with mRCC who underwent PN between 1996 and 2011 were identified. Demographic, clinical, and pathologic variables were collected. Non-parametric statistics and log-rank tests were used. Cancer specific survival (CSS) was estimated using Kaplan-Meier method according to presentation, tumor size, and presence of metastatic disease, from the time of PN to last follow-up or death. Results: The median age at PN was 57 years (range 32-84). 8 patients presented with bilateral synchronous renal masses; 17 presented with a metachronous contralateral renal mass; and 5 presented with a unilateral renal mass (including 3 in a solitary kidney). Median follow-up after PN was 32 months (range 1-184). Overall, 23 patients (77%) died of disease at a median of 27 months (range 7-86) after PN. Patients who underwent PN for a metachronous contralateral renal mass had a median CSS of 61 months compared to those with bilateral synchronous or unilateral renal masses (CSS 26.5 months, HR 2.98, p =.012 and CSS 31, HR 2.12, p =.069, respectively). Patients who underwent PN for a renal mass ≤4cm and >4cm had a median CSS of 42 and 26.5 months, respectively (HR 2.49, p =.037). Median CSS for patients with and without metastatic disease at original diagnosis was 27 and 61 months, respectively (HR 2.85, p =.013). In this study, patients who became M0 after metastasectomy did not have improved CSS compared to patients who did not (42 and 32 months, p =0.152). Conclusions: Our findings suggest that the burden of disease at initial diagnosis, timing of presentation of the PN index lesion, and the size of the renal mass at PN play an important role in survival. These factors should be taken into consideration when determining which patients would benefit from PN in the setting of mRCC.

45: Enucleation of Renal Cell Carcinoma with Ablation of Tumor Base: Is Cancer Control Comparable to Partial Nephrectomy?

2006 ◽  
Vol 175 (4S) ◽  
pp. 16-16
Author(s):  
Alexander Kutikov ◽  
Lindsay K. Fossett ◽  
Thomas J. Guzzo ◽  
Alan J. Wein ◽  
Keith N. Vanarsdalen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Partial Nephrectomy ◽  
Renal Cell ◽  
Cancer Control

Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy

2020 ◽  
Vol 7 (3) ◽  
pp. 20-25
Author(s):  
Lauren Nahouraii ◽  
Jordan Allen ◽  
Suzanne Merrill ◽  
Erik Lehman ◽  
Matthew Kaag ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Renal Mass ◽  
Tumor Stage ◽  
High Grade ◽  
Renal Masses ◽  
Histologic Heterogeneity ◽  
Adequate Sampling ◽  
Renal Mass Biopsy

Pathologic characteristics of extirpated renal cell carcinoma (RCC) specimens <7  cm were reviewed to get better information on technical nuances of renal mass biopsy (RMB). Specimens were stratified according to tumor stage, nuclear grade, size, histology, presence of lymphovas-cular invasion (LVI), necrosis, and sarcomatoid features. When considering pT1 (0–7 cm) tumors pT1b (4–7 cm), RCC masses were more likely to have necrosis (43% vs 16%, P < 0.001), LVI (6% vs 2%, P = 0.024), high-grade nuclear elements (29% vs 17%, P < 0.001), and sarcomatoid features (2% vs 0%, P = 0.006) compared with pT1a (0–4 cm) tumors. Additionally, pT3a tumors were more highly associated with necrosis (P = 0.005), LVI, sarcomatoid features, and high-grade disease (P for all < 0.001) when compared to pT1 masses. For masses <4 cm, pT3a cancers were more likely to demonstrate necrosis (38% vs 16%, P < 0.001), LVI (10% vs 2%, P = 0.037), high-grade nuclear elements (31% vs 17%, P = 0.05), and sarcomatoid features (3% vs 0%, P = 0.065) compared to pT1a tumors. Similarly, for masses 4–7 cm, pathologic T3a tumors were significantly more likely to have sarcomatoid features (16% vs 2%, P < 0.001) and LVI (28% vs 6%, P < 0.001) compared to pT1b tumors. In summary, pT3a tumors and those RCC masses >4 cm exhibit considerable histologic heterogeneity and may harbor elements that are not easily appreciated with limited renal sampling. Therefore, if RMB is considered for renal masses greater than 4 cm or those that abut sinus fat, a multi-quadrant biopsy approach is necessary to ensure adequate sampling and characterization of the mass.

Sign in / Sign up

Export Citation Format

Share Document